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Abstract: 
Inflammatory myopathies such as dermatomyositis and polymyositis are well recognized 
paraneoplastic syndromes. Little is known, however, about necrotizing myopathies in 
association with cancer. We here describe a case of paraneoplastic necrotizing myopathy with 
a mild inflammatory infiltrate in a patient with adenocarcinoma. After the rapid development 
of a severe, disabling muscle weakness, the patient experienced near complete recovery 
within four months under oral prednisone treatment. In the context of the presented case, we 
will review current knowledge about paraneoplastic necrotizing myopathies. 
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Introduction 
In contrast to inflammatory myopathies, paraneoplastic necrotizing myopathy is a very rare 
clinical entity [1]. Symptoms can mimic polymyositis (PM) or dermatomyositis (DM) with 
symmetrical, predominantly proximal muscle weakness of acute or subacute onset [1-2]. 
Necrotizing myopathy has been associated with gastrointestinal tumors, small cell lung 
cancer, and breast cancer, among others [3]. Here we report a case of paraneoplastic 
necrotizing myopathy with a mild inflammatory component and near complete recovery. 
 
Case description 
A 75 year-old woman developed muscle weakness first affecting the proximal muscles of her 
legs, then of her arms. During the initial workup, elevated liver enzymes where noticed, and 
an abdominal CT scan revealed a peripancreatic tumor mass.  
Whipple resection disclosed a 7 cm well demarcated encapsulated peripancreatic carcinoma in 
lymphatic tissue most probably representing a lymph node metastasis of a solid 
adenocarcinoma (figure 1). Resection borders as well as 17 regional lymph nodes were free of 
tumor. The tumor tissue exhibited cytokeratin immunoreactivity (CK7, CK5/6, CK19 but not 
CK20) and a weak positivity for WT1. All other immunohistochemical markers (trypsin, beta-
HCG, inhibin, p63, cdx-2, TTF1, melan A, estrogenreceptor, BerEP4, HepPar1 and 
synaptophysin) were negative. Based on the conventional histology and 
immunohistochemical results, no clear diagnosis concerning a possible primary tumor could 
be made. Intraoperatively, no other abnormalities were noted. 
Within eight weeks, the patient was wheelchair-bound. The respiratory muscles were also 
affected. The forced expiratory volume declined to 1.5 l. The profound proximal symmetrical 
tetraparesis with areflexia was not associated with sensory symptoms or pain. The integument 
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was intact; in particular no rash was noted. Electromyography of proximal muscles exhibited 
sustained spontaneous activity, consistent with myopathy. 
The search for a primary tumor including fluorodeoxyglucose positron emission tomography 
(PET), MRI of brain and spinal cord, CT chest, gastroscopy, colonoscopy, gynecological and 
urological exam, thyroid gland ultrasound and liver biopsy was negative. Pathological 
laboratory results on admission to our department included creatine kinase (CK) 6794 U/l 
(<67), lactic acid dehydrogenase (LDH) 3460 U/l (normal range: 240-420), aspartate 
aminotransferase (AST) 626 U/l (10-35), alanine aminotransferase (ALT) 905 U/l (10-35), 
and gamma-glutamyl transferase (GGT) 71 U/l (35-104). Levels of tumor markers CA125, 
CA15-3, CA19-9, CA72-4 and carcinoembryonic antigen (CEA) were unremarkable. 
Cerebrospinal fluid analysis was normal. Immunological parameters, including anti-signal 
recognition particle (SRP) antibodies and anti-CNS antibodies (anti-Yo, -Ri, -Hu, -
amphiphysin, -CV2, -Ta/Ma2, -Ma, -recoverin) were negative, as were serological tests for 
hepatitis and HIV. 
A biopsy of the quadriceps vastus lateralis muscle showed extensive muscle fibre necrosis, 
regenerating fibres and only mild endomysial lymphocytic infiltrates, mainly localized close 
to necrotic muscle fibres. Lymphocytes did not invade intact muscle fibres. Membrane attack 
complex (MAK, C5b-9), which is typically present on endomysial capillaries in DM, was 
detected on necrotic fibres but not on endomysial capillaries. In addition to the endomysial 
expression of major histocompatibility complex class I (MHC-I), in this biopsy, it was present 
in necrotic and regenerating, but only on a subset of intact mature muscle fibres (figure 2). An 
extensive mainly acute necrotizing myopathy with mild inflammatory infiltrates was 
diagnosed. In the clinical context, a paraneoplastic origin was assumed.  
A brief course of methylprednisolone at 1 g/d for 3 days was administered and the patient was 
referred to neurorehabilitation where oral prednisone (1 mg/kg body weight) was continued, 
in addition to physiotherapy. She recovered substantially, being able to walk without 
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assistance four months later. A year later, the clinical condition was stable and most 
laboratory abnormalities (LDH 562 U/l, AST 66 U/l, ALT 64 U/l, CK 248 U/l) had resolved, 
except GGT (204 U/l). 
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Discussion 
In patients with cancer, symptoms not directly evoked by the tumor spread are usually 
referred to as paraneoplastic. Such syndromes may even precede the identification of the 
tumor. Classical paraneoplastic syndromes affecting the muscle are inflammatory myopathies, 
such as dermatomyositis, which has been shown to be associated with malignancy in 15% of 
cases [4]. First described by Smith in 1969, myopathies with little or no inflammatory 
infiltrate but extensive muscle fibre necrosis have also been associated with malignancies [5]. 
There are, however, no systematic studies assessing the overall risk of cancer in patients with 
this condition. In one case series, three out of eight patients had cancer preceding the 
myopathy or following it within three years of diagnosis [6].  
 
Histopathological findings in paraneoplastic necrotizing myopathies have been reported to be 
heterogeneous, with a picture ranging from sparse, segmental necrotic lesions to massive 
necrosis [5,7]. In four cases with paraneoplastic necrotizing myopathy described by Levin et 
al., an average of 50% of muscle fibres were necrotic (8-100%), while only two of 16 cases 
with inflammatory paraneoplastic myopathy had a higher than 3% fraction of necrotic fibres 
[1]. The pathognomonic hallmark of a necrotizing myopathy in contrast to an inflammatory 
one, however, are sparse inflammatory cells confined to damaged, necrotic muscle fibres; 
while normal-appearing fibres are spared. Furthermore, MHC-I, which is physiologically 
expressed on endomysial capillaries, is also detected on necrotic muscle fibres. It is typically 
up-regulated on almost every muscle fibre in PM. In a series of eight cases with necrotizing 
myopathy, T-lymphocytes and macrophages were found in the vicinity of necrotic fibres, 
while B lymphocytes were absent in most cases [6]. MHC-I immunoreactivity was detected 
on 10% of non-necrotic muscle fibres in six out of the eight cases. The pattern of necrosis in 
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muscle specimens was not uniform between and within subjects and judged as focal in four, 
scattered in five, and diffuse in three cases. 
In the case presented here, about 10% of muscle fibres were necrotic. Macrophages and T-
lymphocytes were detected in the endomysium of the affected muscle biopsy, mainly 
localized close to necrotic muscle fibres. Although the number of lymphocytic cells was 
rather large (see figure 2), the extent of necrosis and immunohistochemistry characteristics 
(MHC-I expression) strongly argued against polymyositis.  
 
Neurological paraneoplastic syndromes seem to be triggered by the response to ”onconeural 
antigens” that are expressed only in the tumor cell and in the nervous system, thereby 
inducing an immune response to both tumor and antigen-expressing neural structures. 
Knowledge about mechanisms causing paraneoplastic syndromes affecting the muscle is 
scant. In inflammatory paraneoplastic myopathies, T cell-mediated immune responses as well 
as humoral factors seem to be involved [3]. The small number of inflammatory cells in 
muscle specimens of patients with necrotizing myopathy raises the possibility of a toxic 
molecule mediating the syndrome, but the response to steroids or immunoglobulins is more 
compatible with an immune-mediated process [6]. The mechanism of a putative therapeutic 
response to the epidermal growth factor receptor antibody, cetuximab, remains obscure [2,8].  
 
One striking feature of paraneoplastic necrotizing myopathy is the wide range of reported 
outcomes, from fast progression with no remission to complete recovery [1-2,6,8]. The 
severity of the condition does not always parallel tumor progression [2]. However, since the 
pathophysiology of the disease is still poorly understood, treatment of the underlying cancer 
seems to be the mainstay of therapy. In our case, where the underlying malignancy was not 
unambiguously identified, complete recovery was spontaneous or occurred with oral 
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prednisone treatment only. Additional treatment with steroids (i.v. and/ or orally), intravenous 
immunoglobins, or other immune modulators may be of benefit to some patients.  
 
Clearly, more studies on the pathophysiology and treatment of paraneoplastic necrotizing 
myopathy are warranted, as the condition is severe and outcome differs dramatically among 
patients, which complicates treatment decisions. Muscle pathology findings in this case 
support the view that paraneoplastic inflammatory and necrotizing myopathies might 
resemble a continuum of a condition caused by similar pathogenetic mechanisms, but 
manifested with varying degrees of necrosis and inflammation, rather than two separate 
entities. 
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Figure legends 
 
Figure 1: Whipple resection specimen with a 7 cm encapsulated peripancreatic tumor. A: 
Overview of the tumor tissue (lower right corner) which is well demarcated and embedded in 
lymphatic tissue (probably lymph node). B: Closer view of the tumor tissue with central 
necrosis and solid tumor growth. C: In higher magnification some areas exhibit diffuse tumor 
growth and occasional papillary projections.  
 
Figure 2: A biopsy of the M. vastus lateralis showed an extensive acute necrotizing myopathy 
with mild inflammatory infiltrates. HE: On the haematoxylin & eosin staining (HE) numerous 
necrotic muscle fibres were seen (black stars) beside basophilic regenerating fibres (examples 
are marked by black circles). Some necrotic fibres were undergoing myophagocytosis (black 
arrowhead). MHC-I: Major histocompatibility complex class I was detected in an even 
distribution on necrotic fibres (black circles) and on the sarcolemma of some muscle fibres 
(black stars). Many fibres, however, lacked expression of MHC-I. MAK: Membrane attack 
complex was deposited in necrotic fibres (brown staining) but was not detectable on 
endomysial capillaries. In immunohistochemistry on consecutive sections, numerous CD68 
positive macrophages were present in the endomysium, mainly in vicinity of and within 
necrotic fibres (black stars). Considerably fewer CD3 positive T lymphocytes, mainly CD8 
positive ones, were present in the endomysium, mainly in the vicinity of necrotic fibres (black 
stars). They did not invade intact muscle fibres. Scale bar: 100 m. 
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